Clinical trials: Neuroendocrine Tumors, NET
Neuroendocrine Tumors
Investigation of the Effects of Diet on the Measurement of Plasma Chromogranin in NET Patients
Measurement of plasma chromogranin A remains the most commonly used biomarkers for both screening and monitoring of patients with gastro-entero-pancreatic neuroendocrine tumours (GEP-NET), despite several limitations that…
- Trial name
- DIB-NET (NCT03288402)
- Testing
- ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast
- Where
- United Kingdom
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- University Hospitals Coventry and Warwickshire NHS Trust
Neuroendocrine Tumors
Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET
Clinical data from uncontrolled retrospective or prospective studies have initially demonstrated antiproliferative effects of lanreotide in limited number of patients lanreotide Autogel® has recently been approved in more than 40…
- Trial name
- NCT03083210
- Testing
- Lanreotide
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center